You are here: Industry Insights > CAPLYTA

News List

Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults Drugs
December 27, 2021
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders...
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA for Bipolar Depression americanpharmaceuticalreview
February 25, 2021
Intra-Cellular Therapies has recently submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for two indications for CAPLYTA (lumateperone): 1) as monotherapy; and 2) as adjunctive therapy with lithium or ...
Intra-Cellular Therapies Announces Availability of CAPLYTA for Schizophrenia americanpharmaceuticalreview
March 27, 2020
Intra-Cellular Therapies announced CAPLYTA (lumateperone) is now available to pharmacies in the U.S. CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults.
Intra-Cellular nabs nod for schizophrenia drug after FDA twists fiercepharma
December 31, 2019
Intra-Cellular Therapies had quite a journey toward an FDA decision on its antipsychotic contender. It involved mixed clinical data, a canceled advisory committee meeting and a three-month review extension.
FDA Approves Schizophrenia Treatment americanpharmaceuticalreview
December 24, 2019
Intra-Cellular Therapies announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults.